New Imaging Biomarkers Predictive of MA Progression
Recruiting
N/A
Interventional Study
Alzheimer Disease
Magnetic Resonance Spectroscopy
Ultra High Field 7T
Progression of Disease
MR Biomarkers
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 60 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 80 (estimated)
- Sponsor
- Poitiers University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death.
Ultra-high field imagi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* French-speaking patients aged 60 to 90 years,
* Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process,
\*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by …
Contacts